of a priority review voucher, except in the case of such an application that was pending as of October 1, 2015, in which case the sponsor of such pending application shall notify the Secretary not later than 30 days after the date on which such voucher is awarded. (e) Fees The sponsor of an application that is the subject of a priority review voucher shall be subject to the fees required under section 744A. (f) Clarification Nothing in this section affects any period of exclusivity under this Act or the protection of any patent. (g) Revocation The Secretary may revoke any priority review voucher awarded under subsection (b) if the drug for which such voucher was awarded is not marketed in the United States within the 365-day period beginning on the date of the approval of such drug. (h) Sunset The authority of the Secretary to carry out the generic priority review voucher program under this section shall terminate on October 1, 2022. . 202. Tropical disease product application Section 524(a)(4)(A) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360n(a)(4)(A) ) is amended— (1) in clause (i), by striking and